RenovoRx Announces Peer-Reviewed Publication Highlighting the TAMP™ Platform's Potential to Improve Chemotherapeutic Delivery for Locally Advanced Pancreatic Cancer

RenovoRx (Nasdaq: RNXT) announced a peer-reviewed publication in Case Reports in Oncology. The study, led by researchers at Hackensack Meridian Health, showed promising results for two locally advanced pancreatic cancer patients treated with the company's TAMP platform and RenovoCath device. The patients experienced tumor responses and reductions in CA 19-9 markers.

Original reporting
Published Oct 1, 2026, 12:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 1, 2026, 12:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefTechnology
Primary signal
$RNXT
Bullish
medium confidence
Mentioned
$RNXT
Relevance
8/10
AlphAI data visualization · based on globenewswire.com
Decision brief

The 30-second read

$RNXTBullishMed
01

Why it matters

The case series provides the first peer‑reviewed clinical evidence supporting the platform, which could influence valuation and partnership interest.

02

Market read

New clinical data may lift RNXT shares and affect the broader targeted oncology device market.

03

What to watch

Small sample size and lack of control group limit the robustness of the findings.

Relevance 8/10Novelty 8/10Timing: today

Background

RenovoRx (NASDAQ: RNXT) develops the Trans‑Arterial Micro‑Perfusion (TAMP) platform and the RenovoCath device for localized drug delivery.

Company-level read

Ticker impact

$RNXTBullishMedium confidence
Context

RenovoRx announced a peer‑reviewed case series showing tumor response and CA 19‑9 reductions using its FDA‑cleared RenovoCath TAMP platform in locally advanced pancreatic cancer.

Expected impact

likely upward pressure as investors price in the supportive data.

Evidence & confidence

First disclosure of clinical case results; data are favorable and may improve market perception of the device and pipeline.

Market effects

Strengthens the targeted drug‑delivery device sector and may boost comparable oncology device companies.

Potentially positive for US biotech and medical‑device investors.

Adds to global interest in intra‑arterial chemotherapy approaches.

Counterpoint

Early case series may not translate to larger trials; investors should watch for Phase III results before committing.

Key entities

  • RenovoRx, Inc.

    US‑listed biotech developing the TAMP platform.

  • Hackensack Meridian Health Jersey Shore University Medical Center

    Site where the case series was conducted.

Related articles

$RNXTMed

RenovoRx Inc (RNXT) (Q3 2026) Earnings Call Highlights: Record Revenue, Expanding

RenovoRx Inc (RNXT) reported Q3 2026 record revenue of $1.07M, up 17% sequentially. CEO Sean Bagai discussed potential impacts of Razin-Q approval on pancreatic cancer treatment and commercialization plans. The company has 26 active commercial centers, with a target of 36 by year-end. Phase III TIGER-PACT trial data is expected in H2 2027. Gross margin was 82%, and cash position is $10.4M. Full-year 2026 revenue guidance remains $3.75M-$4.25M.

$RNXTMed

RenovoRx Reports Record Third Quarter 2026 Revenue Exceeding $1 Million Active Commercial Cancer Center Customers Increased to 26 and Total Commercial Funnel…

RenovoRx, Inc. (RNXT) filed an SEC Form 8-K — Results of Operations and Financial Condition. RenovoRx Reports Record Third Quarter 2026 Revenue Exceeding $1 Million Active Commercial Cancer Center Customers Increased to 26 and Total Commercial Funnel Grows to More Than 65 Centers Maintains 2026 Annual Revenue Guidance of $3.75M to $4.25M First Physician-Driven Expansion

$RNXTMedAI 8/10

RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial

RenovoRx (Nasdaq: RNXT) announced the first patient has enrolled in the PRISM-TAMP trial, evaluating its TAMP platform for borderline resectable pancreatic cancer. The trial, sponsored by the University of Vermont, aims to assess tumor regression and safety. RenovoRx reported $1.1M in 2025 RenovoCath sales and $909K in Q2 2026. The company expects topline data from its Phase III TIGeR-PaC trial in late 2027.

$RNXTLow

Biotech Stocks At 52-Week Highs - RNXT +12%, BLSM, RVTY, ATRC, BFRI

Several biotech stocks hit 52-week highs on August 28, 2026. RenovoRx (RNXT) rose 12% to $1.68 after positive Phase 3 trial data. BlossomHill (BLSM) reached $20.61, with FDA Fast Track designation for BH-30643. AtriCure (ATRC) hit $49.98, reporting Q2 revenue of $153.6M. Biofrontera (BFRI) climbed to $1.61 with 32.9% product revenue growth. Revvity (RVTY) reached $130.07, raising full-year revenue guidance to $2.83B-$2.86B.